Press Releases

Latest

Lynparza Phase III PAOLA-1 trial met primary endpoint as 1st-line maintenance treatment with bevacizumab for advanced ovarian cancer
14 August 2019
Calquence granted US Breakthrough Therapy Designation for chronic lymphocytic leukaemia
14 August 2019
Tagrisso significantly improves overall survival in the Phase III FLAURA trial for 1st-line EGFR-mutated non-small cell lung cancer
9 August 2019
Lynparza Phase III PROfound trial in HRR* mutation-selected metastatic castration-resistant prostate cancer met primary endpoint
7 August 2019
Forxiga label updated in the EU in type-2 diabetes
5 August 2019
H1 2019 Results
25 July 2019
Update on US regulatory decision for Farxiga in type-1 diabetes
15 July 2019
Imfinzi granted US Orphan Drug Designation for small cell lung cancer
12 July 2019
Forxiga receives positive EU CHMP opinion for DECLARE-TIMI 58 cardiovascular outcomes data
1 July 2019
Fasenra receives positive EU CHMP opinion for self-administration and the new Fasenra pen, a pre-filled, single-use auto-injector
1 July 2019

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2018 so you should be able to find just what you are looking for.

Explore archive

Contact us

Email the Global Media Relations team at:

global-mediateam@astrazeneca.com

Gonzalo Viña

Head of Global Media Relations

+44 203 749 5916

Kim Blomley

Director Global Media Relations (Oncology)

+44 7385 367659

Matthew Kent

Director Global Media Relations (BioPharmaceuticals)

+44 203 749 5906

Angela Fiorin

Director Global Media Relations (BioPharmaceuticals)

+44 122 334 4690

Jennifer Hursit

Manager Global Media Relations

+44 203 749 5762

Christina Malmberg Hägerstrand

Media Relations Director, Sweden and Nordic-Baltic

+46 855 253 106

Press Releases

Contact us

Subscribe

Follow us

LinkedIn